The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
estradiol · ESTRADIOL 4 ug/1 · Insert · Vaginal · Mayne Pharma
NDC 68308-0747-00 · 1 BLISTER PACK in 1 CARTON / 2 INSERT in 1 BLISTER PACK · NDA · View full market →
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 68308-0747-08) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 5 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
| Type | Number / code | Expires |
|---|---|---|
| patent | 11266661 | Feb 2, 2034 |
| patent | 11266661 | Feb 2, 2034 |
| patent | 10398708 | Nov 21, 2032 |
| patent | 10398708 | Nov 21, 2032 |
| patent | 10471072 | Nov 21, 2032 |
| patent | 10471072 | Nov 21, 2032 |
| patent | 10537581 | Nov 21, 2032 |
| patent | 10537581 | Nov 21, 2032 |
| patent | 11246875 | Nov 21, 2032 |
| patent | 11246875 | Nov 21, 2032 |
| patent | 11241445 | Nov 21, 2032 |
| patent | 11241445 | Nov 21, 2032 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Bryant Ranch Prepack | ESTRADIOL 10 ug/1 | Jul 15, 2026 | Sep 3, 2026 |
| Amneal Pharmaceuticals of New York LLC | ESTRADIOL 10 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Catalent Pharma Solutions LLC | ESTRADIOL 4 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Catalent Pharma Solutions LLC | ESTRADIOL 10 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novo Nordisk | ESTRADIOL 10 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | ESTRADIOL 10 ug/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mayne Pharma | ESTRADIOL 4 ug/1 | Jul 15, 2026 | Jul 29, 2026 |
| Mayne Pharma | ESTRADIOL 10 ug/1 | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Imvexxy — NDC 68308-0747-00," retrieved September 3, 2026, https://drugdashboards.com/drug/68308074700.
Free to cite with attribution — see how the data is put together.